Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents-Reference-Cited by-同舟云学术

Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents

Published:2020-11 Issue: Volume:139 Page:92-98
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tarantino Paolo,Marra Antonio^ORCID,Gandini Sara,Minotti Marta,Pricolo Paola,Signorelli Giulia,Criscitiello Carmen^ORCID,Locatelli Marzia,Belli Carmen,Bellomi Massimo,Curigliano Giuseppe^ORCID

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: a review;Mazzarella;Eur J Canc,2019

2. Abstract CT183: phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies;Curigliano,2019

3. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy;Ascierto;J Clin Oncol,2017

4. First-in-Human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies;Beatty;Clin Canc Res,2017

5. Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor–related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors;Heinhuis;JAMA Oncol,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer;Journal of Thoracic Oncology;2024-05

2. The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting;Cancer Medicine;2024-03

3. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer;Neoplasma;2024

5. Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab;Oncology;2023-08-14